• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said it received a Department of Defense (DoD) Small Business Innovation Research grant to advance the development of a low-cost, non-invasive surface electroporation delivery device and test its use in combination with Inovio's synthetic DNA vaccines against viruses with bioterrorism potential, including hanta, puumala, arenavirus and pandemic influenza.